Athena Athena

X
[{"orgOrder":0,"company":"FarmaMondo","sponsor":"Dompe Farmaceutici","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Domp\u00e9 and The FarmaMondo Group Enter Agreement to Distribute Oxervate in Russia and Other CIS Countries","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"FarmaMondo","sponsor":"Helsinn Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Farma Mondo Group and Helsinn Sign Exclusive Partnership To Commercialize AKYNZEO\u00ae In The Baltic Region","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by FarmaMondo

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Under the terms of the agreement, Farma Mondo will manage the commercialization of AKYNZEO® in Estonia and Latvia. AKYNZEO® hard capsules (combination of netupitant/palonosetron), for the treatment of chemotherapy-induced nausea and vomiting (CINV) in adults.

            Lead Product(s): Netupitant,Palonosetron

            Therapeutic Area: Gastroenterology Product Name: Akynzeo

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Helsinn Group

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership November 28, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Dompé farmaceutici and FarmaMondo have inked Managed Access Program distribution agreement appointing the FarmaMondo as the exclusive partner to make Oxervate™ (Cenegermin) available for patients affected by Neurotrophic Keratitis in Russia and other CIS countries.

            Lead Product(s): Cenegermin

            Therapeutic Area: Ophthalmology Product Name: Oxervate

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Dompe Farmaceutici

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement November 26, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY